Continually updated mortality models based on adverse events and end-organ function are better at showing which transplant candidates most urgently require a new heart, according to a study published in the Journal of the American College of Cardiology.

A simple measure of waist circumference could identify chronic heart failure patients who would benefit most from mineralocorticoid receptor antagonists, according to a review published July 25 in JAMA Cardiology.

In following patients with heart failure for up to 15 years, Spanish cardiologists found left ventricular ejection fraction (LVEF) followed an inverse U-shape: LVEF improved for the first year, then plateaued for the rest of the first decade and declined in the following years—especially before death.

Italian physicians reported what they believe to be “unprecedented clinical improvement” from interleukin-1 suppression in a patient with dilated cardiomyopathy.

Twice as many U.S. deaths due to cardiac amyloidosis were reported in 2015 than in 1979, but a study in JAMA Cardiology suggests the disease remains vastly underdiagnosed.

Despite decreases in heart failure (HF) incidence and mortality rates in ambulatory patients, mortality remains higher for women, according to a new study published July 16 in the Canadian Medical Association Journal.

Stem cells can be used to “encourage” better function in heart failure (HF) patients in the U.K., according to a recent stem cell therapy trial spearheaded by researchers from the University of Edinburgh. Harvested from bone marrow, the stem cells, which were able to generate new cardiac tissue and blood vessels, had a success rate of 80 percent.

Despite guidelines and quality improvement efforts, many people with heart failure with reduced ejection fraction (HFrEF) aren’t prescribed the recommended medications. And among those who are, fewer than one-fourth receive optimal doses, according to a registry analysis of ambulatory patients.